Background: The incidence of colorectal cancer in patients(pts) under the age of 50 has been steadily on rising over the last two decades. This is in sharp contrast to average onset CRC where there has been a decline. Little is known about clinical behavior and biology of metastatic CRC in the growing YO population. Methods: We defined YO as < 45 yo and AO as > 50 yo. To better understand the differences in biology of early onset rectal tumors, we tabulated the clinical characteristics, genomics using next generation sequencing(MSK-IMPACT), treatments and outcomes in 175 metastatic pts with EO CRC, treated at Memorial Sloan Kettering Cancer Center between 2014 and 2017 and compared these cases to a cohort of AO M CRC cases (n ¼ 413) with CRC related hereditary syndromes such as Lynch Syndrome and inflammatory bowel disease were excluded. AO (p ¼ 0.194) . Among genetic characteristics mutational burden and copy number comparison showed no significant differences between the groups. Conclusions: Our series describes a comprehensive clinical and genomic profile of EO mCRC. In contrast to prior reports YO does not appear to be associated with more aggressive disease and there was no difference in treatment modalities. Detailed genomic and clinical characteristics will be presented. Legal entity responsible for the study: Andrea Cercek. Background: Octogenarians have higher rates of comorbidity that are associated with a poor prognosis. Few studies have identified prognostic factors of elderly patients (pts) with colorectal cancer (CRC), so their optimized care strategies remain controversial. Charlson comorbidity index (CCI) is the most widely used clinical scoring system to predict the survival of patients with malignancies. The aim of this study was to investigate the prevalence of comorbidity and the prognostic impact of the CCI score for survival among octogenarian pts with CRC in our center. Methods: We reviewed 151 pts referred to Medical Oncology between January 2012 and March 2017. Data on demographics, staging, treatment and survival were collected and analysed. CCI score was independent variable. OS rates was estimated by the Kaplan-Meier method, with differences in survival between groups compared by the log-rank test. Results: We reviewed 151 pts with CRC referred to Medical Oncology between January 2012 and March 2017. Data on demographics, staging, treatment and survival was collected and analysed. CCI score was the independent variable. OS rates was estimated by the Kaplan-Meier method, with differences in survival between groups compared by the log-rank test. Results Octogenarians were a 19% of all pts, 82 (54%) men and 69 (46%) women. The median age was 84 years. There was no difference in performance status (PS) between genders with PS 0-1 in 76%, PS 2 in 26% and PS 3-4 in 10%. Pts were divided into high CCI score (CCI 3; n ¼ 52) and low CCI score (CCI < 3; n ¼ 99) groups for comparative analyses of differences in their short-and long-term outcomes. The overall survival (OS) in pts with a Low CCI Score was longer than that in high CCI score (46 versus 25 months; p < 0.01). High CCI score significantly relates to poorer survival outcome for all stages (p < 0.001). Background: Aging induces meaningful changes in immune system and inflammation response with increase in monocyte-lymphocyte ratio (MLR) and serum lactate dehydrogenase (LDH) levels. Notably, high levels of these serum biomarkers are associated with poor prognosis in many tumors. We aim to explore the prognostic role of baseline (i.e. before first line chemotherapy) MLR and LDH levels in elderly patients (pts) with metastatic colorectal cancer (MCRC). Methods: A retrospective analysis of a consecutive cohort of 120 elderly (>70 years) pts treated for MCRC between 2004 and 2017 at the Oncology Department of Aviano National Cancer Institute and University Hospital of Udine (Italy), was conducted. The prognostic role of MLR and LDH levels on overall survival (OS) was investigated through uni-and multivariate Cox regression analyses. Results: At a median follow-up of 50.83 months, median OS was 19.96 months. Overall, 46 pts (38%) presented a right cancer, 43 pts (36%) a left cancer and 30 pts (25%) a rectal one. In 8 (8%) and 47 (50%) pts a mutation of BRAF or KRAS was detected, respectively. Liver (36%), lymph-nodes (22%), peritoneum (22%) and lung (17%) were the most frequent sites of metastasis. Noteworthy, 22 pts (18%) had undergone a metastasectomy. High levels of LDH (>480 U/L) and MLR (>0.45, obtained with ROC curve) were discovered in 23 (32%) and 51 (42%) patients respectively. By univariate analysis, high levels of LDH (HR 2.81, p ¼ 0.001), MLR (HR 2.26, p < 0.001) or both (HR 6.42, p < 0.001) and node involvement at diagnosis (pN2 vs. pN0 HR 2.15, p ¼ 0.019; pN3 vs. pN0 HR 2.69, p ¼ 0.052) were associated with worse OS. Metastasectomy (HR 0.47, p ¼ 0.009), tumor resection (HR 0.50, p ¼ 0.010) and left sidedness (HR 0.53, p ¼ 0.01) were associated with better OS. By multivariate analysis, high levels of LDH (HR 2.64, p ¼ 0.004), MLR (HR 2.21, p ¼ 0.009) or both (HR 4.19, p ¼ 0.019) were independently associated with worse OS. Conclusions: High baseline levels of LDH, MLR or both are unfavorable independent prognostic factors in elderly pts treated with first line chemotherapy for MCRC. These preliminary results emphasize the need of prospective studies to validate these costeffectiveness biomarkers in this subgroup of pts. Legal entity responsible for the study: University of Udine. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
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